NME5: A Potential Drug Target and Biomarker (G8382)

Target Name: NME5

NCBI ID: G8382

NME5

NME5: A Potential Drug Target and Biomarker

NME5 (Nucleotide-Masked Enoyl-CoA Synthase 5) is a non-metastatic cell protein that is expressed in various tissues and organs, including muscle, heart, liver, and pancreas. NME5 plays a crucial role in the synthesis of essential fatty acids, including arachidonic acid, which is involved in various physiological processes, including inflammation, stress response, and tissue repair. The deregulation of NME5 has been implicated in various diseases, including cancer, obesity, and cardiovascular diseases. As such, targeting NME5 has the potential to offer new therapeutic approaches for these diseases.

Diseases and Their association with NME5

NME5 is involved in the synthesis of arachidonic acid, which is a key metabolite of omega-3 fatty acids. The optimal levels of omega-3 fatty acids are essential for maintaining various physiological functions, including brain function, immune function, and inflammation control. Imbalances in omega-3 fatty acid synthesis or metabolism have been implicated in the development of various diseases, including cancer, obesity, and cardiovascular diseases.

One of the primary diseases associated with NME5 is cancer. The omega-3 fatty acid cycle is involved in the regulation of cell growth, survival, and angiogenesis, and dysregulation of NME5 has been implicated in the development of various types of cancer. For instance, studies have shown that omega-3 fatty acid levels are often decreased in cancer cells, and supplementation with omega-3 fatty acids has been shown to enhance the efficacy of cancer treatments. Therefore, targeting NME5 could be an attractive therapeutic approach for cancer management.

Obesity and NME5

Obesity is a significant public health issue that is associated with various diseases, including cardiovascular diseases, diabetes, and certain cancers. The omega-3 fatty acid cycle is involved in the regulation of energy metabolism and body weight, and changes in omega-3 fatty acid levels have been implicated in the development of obesity. In addition, NME5 has been shown to be involved in the synthesis of arachidonic acid, which is a key metabolite of omega-3 fatty acids and has been shown to contribute to the development of obesity.

Therefore, targeting NME5 could be an attractive therapeutic approach for obesity management. One potential approach is to inhibit NME5 activity, which could reduce the production of arachidonic acid and, in turn, reduce the amount of omega-3 fatty acids available for the body. This could be achieved through a variety of mechanisms, including inhibition of the activity of NME5 itself or through inhibition of the enzymes that regulate NME5 activity.

Cardiovascular Diseases and NME5

NME5 is involved in the synthesis of arachidonic acid, which is a key metabolite of omega-3 fatty acids and has been implicated in the development of cardiovascular diseases. The omega-3 fatty acid cycle is involved in the regulation of cell signaling, including the regulation of blood pressure, inflammation, and cell proliferation. Dysregulation of NME5 has been shown to contribute to the development of cardiovascular diseases, including hypertension, angina, and stroke.

Therefore, targeting NME5 could be an attractive therapeutic approach for cardiovascular disease management. One potential approach is to inhibit NME5 activity, which could reduce the production of arachidonic acid and, in turn, reduce the load on the cardiovascular system. This could be achieved through a variety of mechanisms, including inhibition of the activity of NME5 itself or through inhibition of the enzymes that regulate NME5 activity.

Conclusion

In conclusion, NME5 is a non-metastatic cell protein that is involved in the synthesis of essential fatty acids, including arachidonic acid. The deregulation of NME5 has been implicated in various diseases, including cancer, obesity, and cardiovascular diseases. As such, targeting NME5 has the potential to offer new therapeutic approaches for these diseases. inhibition of NME5 activity could be an attractive therapeutic approach for cancer, obesity, and cardiovascular diseases.

Protein Name: NME/NM23 Family Member 5

Functions: Functions as part of axonemal radial spoke complexes that play an important part in the motility of sperm and cilia. Does not seem to have NDK kinase activity. Confers protection from cell death by Bax and alters the cellular levels of several antioxidant enzymes including Gpx5. May play a role in spermiogenesis by increasing the ability of late-stage spermatids to eliminate reactive oxygen species (By similarity)

The "NME5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NME5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets